{"nctId":"NCT02100475","briefTitle":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","startDateStruct":{"date":"2014-04"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":31,"armGroups":[{"label":"Insulin degludec/liraglutide + Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/liraglutide"]},{"label":"Insulin degludec/liraglutide + Insulin Aspart + Metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin degludec/liraglutide","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec/liraglutide","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion (Visit 28) of NN9068-3952 with insulin degludec/liraglutide + metformin\n* HbA1c (glycosylated haemoglobin) above or equal to 7 percent at Visit 27 of NN9068-3952 trial\n\nExclusion Criteria:\n\n* Clinically significant diseases of the major organ systems\n* Screening calcitonin above or equal to 50 ng/L","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Haemoglobin)","description":"Change from baseline in HbA1c after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.94"},{"groupId":"OG001","value":"-0.14","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Change from baseline in body weight after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.1"},{"groupId":"OG001","value":"1.5","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Confirmed Hypoglycaemic Episodes","description":"Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \\< 3.1 mmol/L (56 mg/dL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Back pain","Lipase increased","Abdominal pain","Amylase increased","Anaemia"]}}}